Assessing Cosopt Switch Patients

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmaceutical Research Network
• Treatments: Dorzolamide; Maleic acid; Timolol

Criteria

Inclusion Criteria:

• adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension

• the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM

• visual acuity should be 20/200 or better in each eye

Exclusion Criteria:

• contraindications to study drugs

• anticipated change in systemic hypotensive therapy during the trial

• use of any corticosteroids by any route in the three months immediately prior to Visit 2